Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
• Developing novel therapeutics which enhance the removal of dysfunctional mitochondria, promoting cell health and function • MTX325 is a potentially disease-modifying treatment for Parkinson’s Disease with clinical trial due to start imminently • Backed by blue chip international investors Cambridge, UK – March 14, 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech […]